Abstract：Objective To study the safety of allylestrenol combined with dydrogesterone in the treatment of threatened miscarriage(TM)patients. Methods A total of 62 TM patients in our hospital from were randomly divided into a single group(n=31)and a combined group(n=31).The single group was treated with dydrogesterone,and the combined group was treated with allylestrenol combined with dydrogesterone.The curative effect,improvement time of symptoms,endocrine hormone [progesterone(P),estradiol(E2),β-human chorionic gonadotropin(β-hCG)],uterine blood flow parameters [pulsatility index(PI),resistance index(RI)],adverse reactions and pregnancy outcomes were compared between the two groups. Results The total effective rate of the combined group was,which was higher than that of the single group(P<0.05);compared with the single group,the improvement time of vaginal bleeding and low back and abdominal pain in the combined group was shorter(P<0.05);after treatment,compared with the single group,the levels of P,E2,and β-hCG in the combined group were higher(P<0.05);after treatment,compared with the single group,the levels of PI and RI in the combined group were lower(P<0.05);the incidence of adverse reactions in the combined group was,which was not significantly different from that of the single group(P>0.05);the success rate of miscarriage prevention in the combined group was,and the full-term delivery rate was,which were higher than those of the single group and,and the miscarriage rate was,which was lower than that of the single group(P<0.05). Conclusion The application of allylestrenol combined with dydrogesterone in TM can improve the curative effect,improve the levels of endocrine hormones and uterine blood flow,effectively relieve clinical symptoms,improve pregnancy outcomes,and have good safety.
李志刚, 闫淑芬, 戚瑞鹤, 刘陆燕. 烯丙雌醇联合地屈孕酮治疗先兆流产患者的安全性研究[J]. 哈尔滨医药, 2026, 46(2): 41-44.
Li Zhigang, Yan Shufen, Qi Ruihe, Liu Luyan. A Study on the Safety of Allylestrenol Combined with Dydrogesterone in the Treatment of Threatened Miscarriage Patients. journal1, 2026, 46(2): 41-44.
[1] 陈瑶,黄娟娟,黄燕,等.黄体酮与间苯三酚联合应用对先兆流产产妇围生结局与血红素氧合酶-1表达的影响[J].临床医学,2018,38(7):46-47. [2] 许茜,毕琳,陈圆圆.固肾安胎丸联合地屈孕酮对先兆流产患者性激素及血清HCG的影响[J].湖北中医药大学学报,2023,25(3):67-70. [3] 谢辛,孔北华,段涛.妇产科(第9版)[M].北京:人民卫生出版社,2018,170-174. [4] 赵锦丽,王彩丽,鲁予静.滋肾育胎丸联合地屈孕酮治疗早期先兆流产合并绒毛膜下出血的效果[J].中国实用医刊,2020,47(6):105-108. [5] 习智贞. 地屈孕酮联合黄体酮对先兆流产保胎率及对血绒毛膜促性腺激素、孕酮、雌二醇的影响[J].黑龙江医药科学,2023,46(5):87-88,91. [6] 魏占超,杨春霞,万颖,等.补肾化瘀安胎方联合地屈孕酮治疗早期先兆流产合并绒毛膜下血肿疗效及对孕酮、绒毛膜促性腺激素、免疫炎性因子的影响[J].现代中西医结合杂志,2022,31(14):1973-1976. [7] Nesreen A A Shehata,Hamada A A Ali,Abd El Gany M A Hassan#magtechI#,et al.Doppler and biochemical assessment for the prediction of early pregnancy outcome in patients experiencing threatened spontaneous abortion[J].Int J Gynaecol Obstet,2018,143(2):150-155. [8] 潘建凤,方瑶,颜惠芳,等.滋肾育胎丸联合地屈孕酮对先兆流产绒毛下血肿患者HCG水平、出血面积的影响[J].湖北中医药大学学报,2022,24(5):77-79. [9] 梁玉莲,梁宏正,陆婵丽,等.补肾活血方联合地屈孕酮治疗早期先兆流产合并绒毛膜下血肿疗效观察[J].海南医学,2021,32(16):2084-2087. [10] 尚聪敏. 盐酸利托君联合地屈孕酮对先兆流产患者血清β-人绒毛膜促性腺激素、孕酮及雌二醇水平的影响[J].实用临床医药杂志,2019,23(18):122-124,128. [11] 陈悦,艾美华.黄体酮联合烯丙雌醇对高龄先兆流产患者妊娠结局及血清糖类抗原125、人绒毛膜促性腺激素、孕酮水平的影响[J].中国性科学,2021,30(9):101-103. [12] 阮彦颖,郭玲.烯丙雌醇联合地屈孕酮治疗先兆流产的疗效及对内分泌激素的影响[J].临床合理用药,2023,16(27):142-145.
2026, Vol. 46 
